New hope for Hard-to-Treat breast cancer: first human trial begins
NCT ID NCT05304962
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new oral drug called RGT-419B, given alone or with hormone therapy, in 64 adults with a specific type of advanced breast cancer (HR+/HER2-) that has worsened after prior treatment. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might slow or shrink the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RGT-419B (oral drug) alone or with hormonal therapy
What this could lead to
If successful, this could point toward a new treatment option for people with advanced breast cancer that has stopped responding to current therapies.
What could go wrong
This is a very early Phase 1 trial with only 64 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hem-Onc Associates of the Treasure Coast
ACTIVE_NOT_RECRUITINGPort Saint Lucie, Florida, 34952, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02142, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
New York Cancer and Blood Specialists
RECRUITINGPort Jefferson Station, New York, 11776, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University California, Los Angeles
RECRUITINGLos Angeles, California, 90404, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, San Diego
RECRUITINGLa Jolla, California, 92037, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••